These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37834060)

  • 1. Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 Gangliosidosis.
    Vyas M; Deschenes NM; Osmon KJL; Chen Z; Ahmad I; Kot S; Thompson P; Richmond C; Gray SJ; Walia JS
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma G
    Blondel A; Kraoua I; Marcelino C; Khrouf W; Schlemmer D; Ganne B; Caillaud C; Fernández-Eulate G; Turki IBY; Dauriat B; Bonnefont-Rousselot D; Nadjar Y; Lamari F
    Mol Genet Metab; 2023 Feb; 138(2):106983. PubMed ID: 36709536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In cellulo examination of a beta-alpha hybrid construct of beta-hexosaminidase A subunits, reported to interact with the GM2 activator protein and hydrolyze GM2 ganglioside.
    Sinici I; Yonekawa S; Tkachyova I; Gray SJ; Samulski RJ; Wakarchuk W; Mark BL; Mahuran DJ
    PLoS One; 2013; 8(3):e57908. PubMed ID: 23483939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The GM2 gangliosidoses databases: allelic variation at the HEXA, HEXB, and GM2A gene loci.
    Cordeiro P; Hechtman P; Kaplan F
    Genet Med; 2000; 2(6):319-27. PubMed ID: 11339652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GM2 gangliosidosis AB variant: first case of late onset and review of the literature.
    Ganne B; Dauriat B; Richard L; Lamari F; Ghorab K; Magy L; Benkirane M; Perani A; Marquet V; Calvas P; Yardin C; Bourthoumieu S
    Neurol Sci; 2022 Nov; 43(11):6517-6527. PubMed ID: 35925454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.
    Karumuthil-Melethil S; Nagabhushan Kalburgi S; Thompson P; Tropak M; Kaytor MD; Keimel JG; Mark BL; Mahuran D; Walia JS; Gray SJ
    Hum Gene Ther; 2016 Jul; 27(7):509-21. PubMed ID: 27197548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
    Tsuji D
    Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/nCas9-Based Genome Editing on GM2 Gangliosidoses Fibroblasts via Non-Viral Vectors.
    Leal AF; Cifuentes J; Quezada V; Benincore-Flórez E; Cruz JC; Reyes LH; Espejo-Mojica AJ; Alméciga-Díaz CJ
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined replacement effects of human modified β-hexosaminidase B and GM2 activator protein on GM2 gangliosidoses fibroblasts.
    Kitakaze K; Tasaki C; Tajima Y; Hirokawa T; Tsuji D; Sakuraba H; Itoh K
    Biochem Biophys Rep; 2016 Sep; 7():157-163. PubMed ID: 28955902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice.
    Lahey HG; Webber CJ; Golebiowski D; Izzo CM; Horn E; Taghian T; Rodriguez P; Batista AR; Ellis LE; Hwang M; Martin DR; Gray-Edwards H; Sena-Esteves M
    Mol Ther; 2020 Oct; 28(10):2150-2160. PubMed ID: 32592687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment.
    Liu Y; Hoffmann A; Grinberg A; Westphal H; McDonald MP; Miller KM; Crawley JN; Sandhoff K; Suzuki K; Proia RL
    Proc Natl Acad Sci U S A; 1997 Jul; 94(15):8138-43. PubMed ID: 9223328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GM2 gangliosidosis associated with a HEXA missense mutation in Japanese Chin dogs: a potential model for Tay Sachs disease.
    Sanders DN; Zeng R; Wenger DA; Johnson GS; Johnson GC; Decker JE; Katz ML; Platt SR; O'Brien DP
    Mol Genet Metab; 2013 Jan; 108(1):70-5. PubMed ID: 23266199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies.
    Leal AF; Benincore-Flórez E; Solano-Galarza D; Garzón Jaramillo RG; Echeverri-Peña OY; Suarez DA; Alméciga-Díaz CJ; Espejo-Mojica AJ
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare Variant of GM2 Gangliosidosis through Activator-Protein Deficiency.
    Brackmann F; Kehrer C; Kustermann W; Böhringer J; Krägeloh-Mann I; Trollmann R
    Neuropediatrics; 2017 Apr; 48(2):127-130. PubMed ID: 28192816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of GM2 Gangliosidosis in Adult Sandhoff Mice Using an Intravenous Self-Complementary Hexosaminidase Vector.
    Osmon KJ; Thompson P; Woodley E; Karumuthil-Melethil S; Heindel C; Keimel JG; Kaemmerer WF; Gray SJ; Walia JS
    Curr Gene Ther; 2022; 22(3):262-276. PubMed ID: 34530708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Gene Transfer of a Hexosaminidase Variant Using an scAAV9.47 Vector Corrects GM2 Gangliosidosis in Sandhoff Mice.
    Osmon KJ; Woodley E; Thompson P; Ong K; Karumuthil-Melethil S; Keimel JG; Mark BL; Mahuran D; Gray SJ; Walia JS
    Hum Gene Ther; 2016 Jul; 27(7):497-508. PubMed ID: 27199088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical consequences of mutations causing the GM2 gangliosidoses.
    Mahuran DJ
    Biochim Biophys Acta; 1999 Oct; 1455(2-3):105-38. PubMed ID: 10571007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two patients from Turkey with a novel variant in the
    İnci A; Cengiz Ergin FB; Biberoğlu G; Okur İ; Ezgü FS; Tümer L
    J Pediatr Endocrinol Metab; 2021 Jun; 34(6):805-812. PubMed ID: 33819415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GM2 gangliosidosis AB variant: novel mutation from India - a case report with a review.
    Sheth J; Datar C; Mistri M; Bhavsar R; Sheth F; Shah K
    BMC Pediatr; 2016 Jul; 16():88. PubMed ID: 27402091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a Bicistronic Vector for Correction of Sandhoff Disease in a Mouse Model.
    Woodley E; Osmon KJL; Thompson P; Richmond C; Chen Z; Gray SJ; Walia JS
    Mol Ther Methods Clin Dev; 2019 Mar; 12():47-57. PubMed ID: 30534578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.